Basic and clinical immunologyChange in prevalence of IgE sensitization and mean total IgE with age and cohort
Section snippets
Study subjects
The methods for ECRHS I and ECRHS II have been published in more detail elsewhere,14, 15 and further information is available from the study Web site (www.ecrhs.org).
In ECRHS I, participating centers were each selected as an area defined by pre-existing administrative boundaries with a population of at least 150,000 people. A community-based sampling frame was used to select randomly at least 1500 men and 1500 women age 20 to 44 years, who were sent a short postal questionnaire. A random sample
Results
A total of 6137 subjects (52.3 %) of the 11,719 subjects who provided a blood sample in the first survey took part in ECRHS II and went on to provide a sample in the second. There was variation in the response between centers (minimum, 25.2% in Bordeaux; maximum, 82.4% in Reykjavik). Overall response rates were lower in younger subjects, subjects with symptoms, and subjects who reported smoking at baseline, with no significant (P > .05) variation in these patterns between centers (see Table E3 in
Discussion
This large multicenter study examined changes in serum specific IgE in young and middle-aged adults. There was no significant change in the prevalence of being sensitized to at least 1 environmental allergen over a 10-year period. There was some evidence that the prevalence of sensitization to at least 1 allergen decreased more in the older age groups than in the younger age groups, but these age-related changes were small in comparison with the differences between cohorts. More recent birth
Coordinating center
Project Leader: P. Burney; Statistician: S. Chinn; Principal Investigator: D. Jarvis; Project Coordinator: J. Knox; Principal Investigator: C. Luczynska; Assistant Statistician: J. Potts; Data Manager: S. Arinze.
Steering committee for ECRHS II
Professor Josep M. Antó, Institut Municipal d'Investigació Mèdica (Institut Municipal d'Investigació Mèdica–Institut Municipal d' Assistència Sanitària), Universitat Pompeu Fabra; Professor Peter Burney, Kings College London (Project Leader); Dr Isa Cerveri, University of Pavia; Professor Susan Chinn, Kings College London; Professor Roberto de Marco, University of Verona; Dr Thorarinn Gislason, Iceland University Hospital; Dr Joachim Heinrich, GSF—Institute of Epidemiology; Associate Professor
Principal investigators and senior scientific team
Belgium: South Antwerp and Antwerp City (P. Vermeire, J. Weyler, M. Van Sprundel, V. Nelen); Estonia: Tartu (R. Jogi, A. Soon); France: Paris (F. Neukirch, B. Leynaert, R. Liard, M. Zureik), Grenoble (I. Pin, J. Ferran-Quentin); Germany: Erfurt (J. Heinrich, M. Wjst, C. Frye, I. Meyer); Iceland: Reykjavik (T. Gislason, E. Bjornsson, D. Gislason, T. Blondal, A. Karlsdottir); Italy: Turin (M. Bugiani, P. Piccioni, E. Caria, A. Carosso, E. Migliore, G. Castiglioni), Verona (R. de Marco, G.
References (31)
- et al.
Is atopy increasing?
Lancet
(1994) - et al.
Increasing prevalence of hay fever and atopy among children in Leipzig, East Germany
Lancet
(1998) - et al.
Increasing prevalence of specific IgE to aeroallergens in an adult population: two cross-sectional surveys 8 years apart: the Copenhagen Allergy Study
J Allergy Clin Immunol
(2000) - et al.
Frequency of atopy in the Arctic in 1987 and 1998
Lancet
(2002) - et al.
Longitudinal changes in allergen skin test reactivity in a community population sample
J Allergy Clin Immunol
(1987) - et al.
Increase in the prevalence of allergen skin sensitization in successive birth cohorts
J Allergy Clin Immunol
(2002) - et al.
A longitudinal study of serum IgE in a community cohort: correlations with age, sex, smoking, and atopic status
J Allergy Clin Immunol
(1987) - et al.
Meta-analysis in clinical trials
Control Clin Trials
(1986) - et al.
Sibship size, birth order and atopy in 11,371 Italian young men
J Allergy Clin Immunol
(1998) - et al.
The association of smoking with sensitization to common environmental allergens: results from the European Community Respiratory Health Survey
J Allergy Clin Immunol
(1999)
The distribution of total and specific serum IgE in the European Community Respiratory Health Survey
J Allergy Clin Immunol
Bauernkinder leiden selten an Heuschnupfen und Asthma
Dtsch Med Wochenschr
Immediate skin reactivity to histamine and to allergens in cohorts of 9 year old school children studied 16 years apart
Clin Exp Allergy
The prevalence of skin-test-positive allergic rhinitis in Danish adults: two cross-sectional surveys 8 years apart. The Copenhagen Allergy Study
Allergy
Increase of allergen-specific immunoglobulin E antibodies from 1973 to 1994 in a Finnish population and a possible relationship to Helicobacter pylori infections
Clin Exp Allergy
Cited by (110)
Does allergy decrease with age?
2024, Revue Francaise d'AllergologieAsthma in an aging world
2023, Asthma in the 21st Century: New Research AdvancesAutoimmune Chronic Spontaneous Urticaria Detection with IgG Anti-TPO and Total IgE
2021, Journal of Allergy and Clinical Immunology: In PracticeAllergic children with extremely high total IgE but no allergen identified in the initial screening panel
2021, Journal of Microbiology, Immunology and InfectionAge-specific changes in the molecular phenotype of patients with moderate-to-severe atopic dermatitis
2019, Journal of Allergy and Clinical ImmunologyAllergic profiles of mothers and fathers in the Japan Environment and Children's Study (JECS): A nationwide birth cohort study
2017, World Allergy Organization Journal
The coordination of ECRHS II was supported by the European Commission as part of their Quality of Life program.
The following bodies supported the local studies in ECRHS II included in this article. Albacete: Fondo de Investigaciones Santarias (grant codes, 97/0035-01, 99/0034-01, and 99/0034-02), Hospital Universitario de Albacete, Consejeria de Sanidad; Antwerp: Fund for Scientific Research—Flanders, Belgium (grant code, G.0402.00), University of Antwerp, Flemish Health Ministry; Barcelona: Sociedad Española de Neumología y Cirugía Torácica, Public Health Service (grant code, R01 HL62633-01), Fondo de Investigaciones Santarias (grant codes, 97/0035-01, 99/0034-01, and 99/0034-02), Consell Interdepartamental de Recerca i Innovació Tecnològica (grant code, 1999SGR 00241) Instituto de Salud Carlos III; Red de Centros de Epidemiología y Salud Pública, C03/09, Red de Bases moleculares y fisiológicas de las Enfermedades Respiratorias, C03/011 and Red de Grupos Infancia y Medio Ambiente G03/176; Basel: Swiss National Science Foundation, Swiss Federal Office for Education and Science, Swiss National Accident Insurance Fund; Bergen: Norwegian Research Council, Norwegian Asthma and Allergy Association, Glaxo Wellcome AS, Norway Research Fund; Bordeaux: Institut Pneumologique d'Aquitaine; Erfurt: GSF—National Research Centre for Environment and Health, Deutsche Forschungsgemeinschaft (grant code, FR 1526/1-1); Galdakao: Basque Health Department; Goteborg: Swedish Heart Lung Foundation, Swedish Foundation for Health Care Sciences and Allergy Research, Swedish Asthma and Allergy Foundation, Swedish Cancer and Allergy Foundation; Grenoble: Programme Hospitalier de Recherche Clinique—Direction de la Recherche Clinique (DRC) de Grenoble 2000 number 2610, Ministry of Health, Direction de la Recherche Clinique, Ministere de l'Emploi et de la Solidarite, Direction Generale de la Sante, Centre Hospitalier Universitaire (CHU) de Grenoble, Comite des Maladies Respiratoires de l'Isere; Hamburg: GSF—National Reasearch Centre for Environment and Health, Deutsche Forschungsgemeinschaft (grant code, MA 711/4-1); Ipswich and Norwich: Asthma UK (formerly known as National Asthma Campaign); Huelva: Fondo de Investigaciones Santarias (grant codes, 97/0035-01, 99/0034-01, and 99/0034-02); Montpellier: Programme Hospitalier de Recherche Clinique—DRC de Grenoble 2000 number 2610, Ministry of Health, Direction de la Recherche Clinique, CHU de Grenoble, Ministere de l'Emploi et de la Solidarite, Direction Generale de la Sante, Aventis (France), Direction Régionale des Affaires Sanitaires et Sociales Languedoc-Roussillon; Oviedo: Fondo de Investigaciones Santarias (grant codes, 97/0035-01, 99/0034-01, and 99/0034-02); Paris: Ministere de l'Emploi et de la Solidarite, Direction Generale de la Sante, Union Chimique Belge—Pharma (France), Aventis (France), Glaxo France, Programme Hospitalier de Recherche Clinique—DRC de Grenoble 2000 number 2610, Ministry of Health, Direction de la Recherche Clinique, CHU de Grenoble; Pavia: Glaxo-SmithKline Italy, Italian Ministry of University and Scientific and Technological Research (MURST), Local University Funding for Research 1998 and 1999; Portland: American Lung Association of Oregon, Northwest Health Foundation, Collins Foundation, Merck Pharmaceutical; Reykjavik: Icelandic Research Council, Icelandic University Hospital Fund; Tartu: Estonian Science Foundation; Turin: Azienda Sanitaria Locale 4 Regione Piemonte (Italy), Azienda Ospedaliera Centro Traumatologico Ospedaliero/Centro Traumatologico Ortopedico—Istituto Clinico Ortopedico Regina Maria Adelaide Regione Piemonte (Italy), Ministero dell'Universitá e della Ricerca Scientifica (Italy), Glaxo Wellcome spa (Verona, Italy); Umeå: Swedish Heart Lung Foundation, Swedish Foundation for Health Care Sciences and Allergy Research, Swedish Asthma and Allergy Foundation, Swedish Cancer and Allergy Foundation; Uppsala: Swedish Heart Lung Foundation, Swedish Foundation for Health Care Sciences and Allergy Research, Swedish Asthma and Allergy Foundation, Swedish Cancer and Allergy Foundation; Verona: University of Verona, MURST, GlaxoSmithKline Italy.
The following bodies supported ECRHS I for centers in ECRHS II. Belgian Science Policy Office, National Fund for Scientific Research; Ministère de la Santé, Glaxo France, Insitut Pneumologique d'Aquitaine, Contrat de Plan Etat-Région Languedoc-Rousillon, Caisse Nationale de l'Assurance Maladie des Travailleurs Salariés, Comité National Contre les maladies Respiratoires et la Tuberculose (90MR/10, 91AF/6), Ministre delegué de la santé, Réseau National de Santé Publique, France; GSF, and the Bundesminister für Forschung und Technologie, Bonn, Germany; Ministero dell'Universitá e della Ricerca Scientifica e Tecnologica, Consiglio Nazionale delle Ricerche, Regione Veneto grant number 381/05.93, Italy; Norwegian Research Council project number 101422/310; Dutch Ministry of Wellbeing, Public Health and Culture, Netherlands; Ministero Sanidad y Consumo FIS (grants #91/0016060/00E-05E and #93/0393), and grants from Hospital General de Albacete, Hospital General Juan Ramón Jiménenz, Consejeria de Sanidad Principado de Asturias, Spain; Swedish Medical Research Council, Swedish Heart Lung Foundation, Swedish Association Against Asthma and Allergy; Swiss National Science Foundation grant 4026-28099; National Asthma Campaign, British Lung Foundation, Department of Health, South Thames Regional Health Authority, United Kingdom; United States Department of Health, Education and Welfare Public Health Service (grant #2 S07 RR05521-28).